View More Recent Stories
-
Arrowhead Pharmaceuticals (ARWR) Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
-
Arrowhead Pharmaceuticals Inc. (ARWR) Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
-
Arrowhead Pharmaceuticals Inc. (ARWR) expands resources for those affected by FCS
-
Arrowhead Pharmaceuticals (ARWR) Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
-
RBC Capital on Arrowhead Pharma (ARWR): 'SRPT Deal Closed; Focus Now Sharpened to Cardiometabolic'
-
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Arrowhead Pharma (ARWR) PT Lowered to $41 at BofA Securities
-
Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q1 EPS by 100c
-
Arrowhead Pharmaceuticals (ARWR) Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics (SRPT)
-
Guidewire Software (GWRE) to Join S&P MidCap 400; Arrowhead Pharmaceuticals (ARWR) to Join S&P SmallCap 600
-
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT), Says DM1 Data Could Move Stock
-
B.Riley Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Arrowhead Pharma (ARWR) PT Raised to $80 at H.C. Wainwright
-
Arrowhead Pharmaceuticals Inc. (ARWR) Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7
-
Arrowhead Pharma (ARWR) PT Lowered to $24 at Bernstein SocGen Group
-
Arrowhead Pharma (ARWR) PT Lowered to $45 at Piper Sandler
-
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Arrowhead Pharma (ARWR) PT Lowered to $26 at Citi
-
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT) on Arrowhead (ARWR) deal
-
Arrowhead Pharmaceuticals (ARWR) Climbs 32% Following Pact with Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals (ARWR) for Multiple Clinical and Preclinical siRNA Programs
-
Piper Sandler Reiterates Overweight Rating on Arrowhead Pharma (ARWR)
-
Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
-
Arrowhead Pharmaceuticals Inc. (ARWR) Submits New Drug Application to U.S. FDA for Plozasiran
-
Arrowhead Pharmaceuticals (ARWR) Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
-
H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Goldman Sachs Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
-
TD Cowen Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Piper Sandler Reiterates Overweight Rating on Arrowhead Pharma (ARWR)
-
Arrowhead Pharmaceuticals (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
-
Arrowhead Pharmaceuticals (ARWR) Receives FDA Breakthrough Therapy Designation for Plozasiran
-
TD Cowen Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
-
TD Cowen Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Arrowhead Pharmaceuticals Inc. (ARWR) to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
-
Piper Sandler Reiterates Overweight Rating on Arrowhead Pharma (ARWR)
-
Arrowhead Pharmaceuticals Inc. (ARWR) to Advance ARO-INHBE and ARO-ALK7 Into Clinical Studies
-
Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 85c
-
Arrowhead Pharmaceuticals (ARWR) Announces $500 Million Strategic Financing Facility with Sixth Street
-
Arrowhead Pharma (ARWR) PT Lowered to $60 at H.C. Wainwright
-
TD Cowen Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Arrowhead Pharmaceuticals (ARWR) to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
-
Arrowhead Pharmaceuticals Inc. (ARWR) Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
